List of Excipients in Branded Drug KYPROLIS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Onyx Pharmaceuticals Inc	KYPROLIS	carfilzomib	76075-101	ANHYDROUS CITRIC ACID
Onyx Pharmaceuticals Inc	KYPROLIS	carfilzomib	76075-101	BETADEX SULFOBUTYL ETHER SODIUM
Onyx Pharmaceuticals Inc	KYPROLIS	carfilzomib	76075-101	SODIUM HYDROXIDE

Kyprolis Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 4, 2026

Kyprolis, the branded carfilzomib injection from Amgen, is an intravenous proteasome inhibitor for multiple myeloma. Its commercial formulation uses a small excipient system centered on sulfobutyl ether beta-cyclodextrin, also known as SBECD or Captisol, with citric acid and sodium hydroxide. The main excipient opportunity is not a simple copy of the finished product. It is the development of alternative lyophilized formulations, ready-to-use presentations, improved reconstitution systems, and supply-chain products that reduce dependence on proprietary cyclodextrin technology.

Kyprolis generated approximately $1.3 billion in annual sales in recent years, making formulation and manufacturing work commercially relevant even as core compound exclusivity approaches maturity [1]. Because carfilzomib is a small molecule, future competition will come through abbreviated new drug applications, patent challenges, hospital-use products, and formulation differentiation rather than biosimilars.

What excipients are used in Kyprolis?

Kyprolis is supplied as a sterile, preservative-free, lyophilized powder for intravenous administration. The FDA prescribing information identifies the following inactive ingredients:

Excipient	Function in Kyprolis	Commercial relevance
Sulfobutyl ether beta-cyclodextrin sodium, SBECD	Solubilization and stabilization of carfilzomib	Highest strategic value; may create dependence on Captisol supply and know-how
Citric acid	pH adjustment and formulation buffering	Commodity excipient with limited standalone differentiation
Sodium hydroxide	pH adjustment	Commodity excipient with limited standalone differentiation
Sterile Water for Injection	Reconstitution diluent, supplied separately	Relevant to hospital workflow and ready-to-use alternatives

The reconstituted product is diluted before intravenous administration. The formulation is designed for stability as a freeze-dried product rather than as a conventional aqueous solution [2].

Why is SBECD important in the Kyprolis formulation?

SBECD is an ionically substituted beta-cyclodextrin used to improve the apparent aqueous solubility of poorly water-soluble drugs. Cyclodextrins form inclusion complexes around hydrophobic drug regions, allowing the active ingredient to be administered in an aqueous environment.

For Kyprolis, SBECD performs several functions:

• increases carfilzomib solubility;
• supports an injectable concentration suitable for hospital preparation;
• helps maintain product uniformity during lyophilization and reconstitution;
• may reduce precipitation during dilution;
• supports a preservative-free intravenous presentation.

SBECD is commercially associated with Ligand Pharmaceuticals’ Captisol technology. A competing manufacturer may be able to use SBECD under a commercial supply arrangement, but the excipient itself does not automatically create freedom to operate for every drug formulation. Separate rights may attach to excipient composition, drug-excipient ratios, manufacturing conditions, reconstitution performance, or use in a specific therapeutic indication.

What formulation is protected by the Kyprolis excipient strategy?

The commercial formulation has several potentially protectable technical elements:

1. The combination of carfilzomib and SBECD.
2. Specific drug-to-cyclodextrin ratios.
3. The pH range and buffer composition.
4. Lyophilization cycle parameters.
5. Residual moisture limits.
6. Reconstitution time and acceptable particulate limits.
7. Dilution into common infusion solutions.
8. Stability after reconstitution and dilution.
9. Container-closure configurations.
10. Manufacturing controls that preserve proteasome inhibitor potency.

A generic manufacturer does not necessarily need to reproduce every formulation attribute. Under the ANDA pathway, it must demonstrate pharmaceutical equivalence and bioequivalence, while meeting applicable quality and labeling requirements. A materially different formulation could require a 505(b)(2) application if it changes the dosage form, route, dosing conditions, excipient system, or clinical use.

Which formulation alternatives could compete with SBECD?

Potential alternatives include:

Formulation route	Technical objective	Commercial potential
Hydroxypropyl beta-cyclodextrin	Replace or reduce SBECD	Moderate; requires comparative solubility and safety work
Sulfobutylether cyclodextrin with different substitution level	Optimize complexation and tolerability	Moderate; may create a differentiated composition
Mixed cyclodextrin system	Improve loading or reconstitution	Moderate to high if it reduces excipient quantity
Surfactant-assisted formulation	Increase solubility without cyclodextrin dependence	Technically attractive but may create infusion tolerability issues
Lipid or nanoparticle system	Improve solubility and exposure	Higher development risk; potentially valuable for subcutaneous or oral programs
Amorphous solid dispersion	Stabilize carfilzomib in a solid matrix	More relevant to nonintravenous products
Ready-to-use liquid	Remove hospital reconstitution step	High workflow value but difficult stability target
Alternative lyophilized cake	Improve reconstitution and shipping stability	Strongest near-term generic and lifecycle opportunity

The most practical opportunity is likely a lyophilized product using the same or a comparable solubilization principle, combined with better reconstitution performance, lower preparation burden, or a more efficient manufacturing process.

When does Kyprolis lose exclusivity?

Kyprolis received FDA approval in 2012 for relapsed or refractory multiple myeloma after at least two prior therapies. The indication later expanded to include combination regimens and earlier-line multiple myeloma treatment [2].

Exclusivity category	Kyprolis position
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Historical orphan protection has expired for the original approved indications
Biologic exclusivity	Not applicable
Small-molecule patent protection	Core protection is in the mid-2020s; listed patent scope and enforceability determine the practical launch date
Generic pathway	ANDA, subject to patent certification and regulatory requirements
505(b)(2) pathway	Potential route for materially different formulations or presentations

The commercial loss-of-exclusivity event may not occur on one date. A generic launch can be delayed by listed patents, pediatric extensions, patent-term adjustment, settlement agreements, manufacturing readiness, and the economics of a hospital-administered oncology product.

What is the Orange Book status of Kyprolis?

Kyprolis is an FDA-approved small-molecule prescription product and is eligible for Orange Book listing. The relevant regulatory questions are whether Amgen has listed patents covering the approved product and whether those patents cover the active ingredient, formulation, method of use, or a combination of those elements.

Orange Book analysis should distinguish:

• patents claiming carfilzomib itself;
• patents covering injectable formulations;
• patents covering SBECD-containing compositions;
• patents covering dosing schedules;
• patents covering combination treatment;
• patents covering lyophilization or reconstitution;
• patents with expiration dates extended by patent-term adjustment or pediatric exclusivity.

An ANDA applicant must certify against each applicable listed patent. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. The certification can trigger patent litigation under the Hatch-Waxman framework.

Which companies are challenging Kyprolis patents?

The principal competitive group is likely to include generic injectable oncology manufacturers with sterile lyophilization capacity. Potential participants in the market include Teva, Sandoz, Fresenius Kabi, Dr. Reddy’s Laboratories, Hikma, Cipla, Sun Pharma, Accord Healthcare, and specialized contract manufacturers.

A company’s ability to challenge Kyprolis depends on more than its patent position. It must also have:

• sterile injectable manufacturing capability;
• validated lyophilization equipment;
• reliable access to SBECD or an alternative solubilizer;
• sufficient oncology distribution infrastructure;
• a strategy for limited-volume hospital accounts;
• the ability to manage hazardous-drug handling requirements;
• a formulation that meets reconstitution and stability specifications.

Public FDA materials should be checked for specific Paragraph IV notices and ANDA litigation. A patent challenge is commercially meaningful only if the challenger has both a viable legal position and a manufacturable product.

What does a Paragraph IV challenge mean for Kyprolis?

A Paragraph IV challenge could produce one of four outcomes:

1. Amgen does not sue, allowing approval after the relevant regulatory period.
2. Amgen sues, triggering a 30-month stay of approval unless resolved earlier.
3. The parties settle with an agreed generic entry date.
4. The challenger prevails or invalidates the asserted patents, enabling earlier launch.

The value of a Paragraph IV strategy depends heavily on whether the challenged patent covers the core molecule or only a narrow formulation or method-of-use claim. A challenge to a narrow formulation patent may leave the reference product exposed to a non-infringing alternative formulation.

What generic entry risks exist for Kyprolis?

Kyprolis has several characteristics that can slow generic entry:

• It is a sterile lyophilized injectable.
• The active ingredient is a potent oncology compound.
• The formulation uses a specialized solubilizing excipient.
• Reconstitution and dilution must be controlled.
• The product is administered in oncology centers and hospitals.
• Multiple approved dosing schedules complicate label design.
• Manufacturing failures can cause substantial batch losses.
• Hospital contracts may favor established suppliers.

The main risks to Amgen are therefore not limited to a traditional generic price discount. A successful competitor could enter with a lower-cost vial, improve supply reliability, offer more favorable purchasing terms, or combine the product with oncology distribution services.

How strong is the Kyprolis patent estate?

The patent estate is strongest where claims cover the active carfilzomib molecule or a narrowly defined injectable composition that is difficult to design around. It is weaker where claims cover broad therapeutic methods, general proteasome inhibition, or formulation parameters that can be replaced without changing the clinical use.

Patent category	Relative defensive value	Design-around potential
Carfilzomib compound claims	High	Low
SBECD-carfilzomib composition claims	High to moderate	Moderate
Lyophilized formulation claims	Moderate	Moderate to high
Reconstitution claims	Moderate	High
Combination-treatment claims	Moderate	High through label carve-outs
Dosing-schedule claims	Moderate	Moderate to high
Manufacturing-process claims	Moderate	Moderate
Container or packaging claims	Low to moderate	High

The strongest commercial defense is a combination of compound, formulation, manufacturing, and method-of-use claims. A narrow excipient patent alone is unlikely to prevent all competition if a generic can use a different cyclodextrin, alter the ratio, or develop an equivalent but non-infringing lyophilization process.

What patent opportunities exist for excipient suppliers?

Excipient suppliers can create value through a layered IP strategy rather than by claiming a commodity ingredient. Potential claim areas include:

• specific SBECD substitution levels;
• defined molecular-weight distributions;
• low-endotoxin injectable grades;
• impurity profiles;
• carfilzomib complexation ratios;
• improved cake structure;
• faster reconstitution;
• reduced foaming;
• reduced aggregation;
• improved stability after dilution;
• container-closure compatibility;
• continuous or intensified manufacturing methods.

A supplier that controls a high-performance injectable grade of SBECD may obtain recurring revenue from reference products, generic manufacturers, and contract development organizations. The commercial opportunity is strongest where the excipient is difficult to replace without additional toxicology, stability, or regulatory work.

Can Captisol create a barrier to generic Kyprolis?

Captisol can create a practical barrier, but not necessarily a permanent legal barrier. A generic company may purchase SBECD, license technology, or use an alternative excipient. The key constraints are grade availability, pharmaceutical quality documentation, supply continuity, and the need to reproduce the reference product’s performance.

The most valuable supplier position is a validated excipient platform with:

• DMF support;
• injectable-grade specifications;
• consistent lot-to-lot substitution;
• regulatory history;
• supply contracts;
• technical support for lyophilization;
• documented compatibility with oncology drug manufacturing.

What licensing deals affect Kyprolis excipients?

Kyprolis was developed by Onyx Pharmaceuticals and became an Amgen product after Amgen acquired Onyx in 2013. The excipient technology is commercially associated with Ligand’s Captisol platform. Licensing and supply arrangements may govern the use of SBECD technology, but the economic terms and product-specific rights are not fully disclosed in public regulatory materials [1, 3].

Relevant deal structures may include:

• excipient supply agreements;
• formulation technology licenses;
• development-stage rights;
• field-of-use restrictions;
• minimum purchase commitments;
• regional rights;
• royalty-bearing rights;
• rights for generic or follow-on products.

For a competitor, the practical question is whether access to SBECD is available on terms compatible with a low-margin injectable generic. If not, an alternative formulation may have greater strategic value than a direct licensed copy.

What FDA regulatory issues apply to a Kyprolis generic?

A conventional generic would generally require an ANDA demonstrating equivalence to the reference listed drug. The applicant must address:

• active ingredient sameness;
• dosage form and route;
• strength;
• sterility;
• particulate matter;
• impurities and degradation products;
• reconstitution performance;
• dilution compatibility;
• stability;
• container closure;
• extractables and leachables;
• labeling and handling requirements.

A different excipient system can create regulatory complexity if it affects pharmacokinetics, tolerability, infusion reactions, or product performance. A materially different presentation may be more appropriate for a 505(b)(2) application.

Kyprolis is not eligible for the FDA biosimilar pathway because carfilzomib is a chemically synthesized small molecule rather than a biologic product regulated under section 351 of the Public Health Service Act.

What commercial opportunities exist beyond a generic Kyprolis vial?

The strongest opportunities are in formulation, manufacturing, and hospital workflow.

Ready-to-use and reduced-reconstitution products

A stable liquid or concentrated presentation could reduce pharmacy preparation time and handling errors. The main technical barrier is maintaining carfilzomib stability in solution while preserving potency and limiting aggregation.

Improved lyophilized presentations

A formulation with faster reconstitution, a more robust cake, lower foaming, or longer in-use stability could command hospital and health-system interest even without a large clinical difference.

Excipient supply

SBECD and other injectable solubilizers represent recurring revenue opportunities. Suppliers can target both branded and generic manufacturers, particularly where regulatory documentation and supply reliability are valued.

Contract development and manufacturing

CDMOs with sterile lyophilization, potent-compound containment, and oncology expertise can offer development services for generic and lifecycle products. The combination of hazardous-drug handling and specialized freeze-drying narrows the field of capable manufacturers.

Regional generic markets

The commercial opportunity is strongest in the United States, Europe, Japan, and high-volume oncology markets. Regional entry may occur before or after U.S. patent expiry depending on local patent rights, regulatory review, and procurement systems.

Combination therapy and method-of-use products

Kyprolis is used with dexamethasone and other antimyeloma agents. Method-of-use patents may protect selected combinations or dosing schedules, but generic labels may use carve-outs where legally and regulatorily permissible. Combination claims therefore create a narrower barrier than compound claims.

How does Kyprolis compare with competing multiple myeloma products?

Product	Active ingredient	Administration	Competitive relevance
Kyprolis	Carfilzomib	Intravenous	High efficacy and intensive infusion workflow
Velcade	Bortezomib	Subcutaneous or intravenous	More convenient subcutaneous option; older product
Ninlaro	Ixazomib	Oral	Avoids infusion-center administration
Darzalex	Daratumumab	Subcutaneous or intravenous	Major antibody competitor in combination regimens
Empliciti	Elotuzumab	Intravenous	Combination-focused antibody therapy

Kyprolis retains commercial value through its clinical positioning, but the intravenous route creates a formulation and administration disadvantage relative to oral and subcutaneous competitors. A ready-to-use or lower-burden presentation could improve its operational position.

What is the revenue exposure from Kyprolis patent expiry?

Kyprolis revenue exposure is material because the product has annual sales near or above $1 billion. The impact of generic entry will depend on launch timing and the number of approved competitors.

Entry scenario	Likely commercial effect
Single generic with delayed launch	Limited early erosion; negotiated hospital pricing
Several generics at once	Rapid vial-price compression and share loss
Authorized generic or settlement launch	Controlled erosion with retained channel access
Formulation-specific challenge	Partial competition, with branded product retaining differentiated supply or label features
Non-infringing alternative formulation	Greater risk if the competitor avoids key formulation claims

The injectable oncology market often experiences slower switching than oral primary-care generics because hospitals value reliable supply, validated preparation procedures, and continuity of treatment. Price erosion can still accelerate once multiple suppliers qualify.

Key Takeaways

• Kyprolis uses SBECD, citric acid, and sodium hydroxide in a sterile lyophilized carfilzomib formulation.
• SBECD is the central excipient asset and the most important supply-chain dependency.
• Captisol-related licensing and supply access can affect generic economics, but alternative solubilizers remain a potential design-around route.
• Kyprolis is a small molecule, so generic competition proceeds through ANDA or, for materially different products, 505(b)(2), not biosimilar approval.
• Compound patent protection is more defensively valuable than narrow reconstitution or formulation claims.
• The strongest commercial opportunities are improved lyophilized products, ready-to-use presentations, injectable excipient supply, and specialized CDMO services.
• Annual Kyprolis sales of approximately $1.3 billion create meaningful revenue exposure as generic entry becomes legally and technically feasible.
• Hospital workflow, sterile manufacturing, hazardous-drug containment, and SBECD availability will influence market entry as much as patent validity.

FAQs

Is SBECD the same as Captisol in Kyprolis?

SBECD is the excipient class used in the formulation. Captisol is the commercial brand associated with Ligand’s sulfobutyl ether beta-cyclodextrin technology.

Can a generic Kyprolis use a different excipient?

Yes. A generic applicant may pursue a different excipient system if it satisfies the applicable FDA equivalence, safety, quality, and performance requirements and does not infringe enforceable patents.

Does Kyprolis have biosimilar competition?

No. Carfilzomib is a chemically synthesized small molecule. Competition would come through generic or 505(b)(2) products rather than biosimilars.

What is the most valuable Kyprolis lifecycle modification?

A stable ready-to-use liquid or a substantially faster-reconstituting lyophilized product would address the principal operational weakness of the current intravenous presentation.

Can an excipient supplier patent a carfilzomib formulation?

Yes. Patentable subject matter may include defined excipient ratios, substitution levels, stability profiles, reconstitution performance, manufacturing processes, and container-closure combinations, provided the claims satisfy applicable patentability standards.

References

1. Amgen Inc. (2024). 2023 annual report. https://www.amgen.com
2. U.S. Food and Drug Administration. (2024). Kyprolis (carfilzomib) prescribing information. https://www.accessdata.fda.gov
3. Ligand Pharmaceuticals Incorporated. (2024). Annual report. https://www.ligand.com
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. https://www.fda.gov/drugs/generic-drugs/abbreviated-new-drug-application-anda-approval-process